SIGA Updates on Progress Its Smallpox Drug Trials For Potential Use Against Monkeypox

• SIGA Technologies Inc (NASDAQ: SIGA) provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox.

• In recent weeks, the company initiated trials in the U.S., the U.K., and Congo to further assess the safety and efficacy of TPOXX in participants with monkeypox.

• These randomized clinical trials are now enrolling patients.

  • Study of Tecovirimat for Human Monkeypox Virus (STOMP; A5418) is a U.S.-based clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). Study investigators aim to enroll more than 500 participants, including children.

  • PLATINUM is a U.K.-based clinical trial commissioned and funded by the National Institute for Health Care and Research (NIHR), intending to recruit at least 500 participants.

  • PALM 007 is a Congo-based clinical trial sponsored by NIAID and Institute National de Recherche Biomédicale (INRB). Study investigators aim to enroll more than 450 participants, including children weighing ≥3 kg and those who are pregnant or breastfeeding.

• In 2018, the FDA approved oral TPOXX for smallpox.

• SIGA disclosed that as of mid-September, it received approximately $76 million of international orders for oral TPOXX from twelve international customers.

• Price Action: SIGA shares are down 0.17% at $9.08 during the market session on the last check Thursday.

See more from Benzinga

• SIGA Technologies Bags New DoD Contract For Monkeypox Treatment

• Trump Has 21 Days To Declare Which Mar-a-Lago Documents He Wants To Keep Off-Limits In Criminal Probe

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.